FY2024 EPS Estimates for REGENXBIO Raised by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of REGENXBIO in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($4.86) per share for the year, up from their previous forecast of ($4.95). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.87) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q4 2024 earnings at ($1.27) EPS, FY2025 earnings at $0.03 EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.70) EPS.

Several other brokerages have also recently commented on RGNX. Raymond James reiterated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research note on Thursday, October 10th. StockNews.com cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, Chardan Capital reissued a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.82.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $7.88 on Friday. The firm has a market cap of $390.41 million, a price-to-earnings ratio of -1.57 and a beta of 1.28. The firm has a fifty day moving average price of $8.42 and a 200 day moving average price of $10.38. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank lifted its holdings in shares of REGENXBIO by 9.9% during the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,227 shares during the last quarter. FMR LLC raised its stake in REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC boosted its holdings in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares in the last quarter. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of REGENXBIO by 19.6% during the second quarter. The Manufacturers Life Insurance Company now owns 18,375 shares of the biotechnology company’s stock worth $215,000 after acquiring an additional 3,015 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.